Clinical Trials · NCT02467920
Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Huazhong University of Science and Technology
- Enrollment
- 349
- Start date
- Aug 2015
- Locations
- 1 site, China
- Primary endpoint
- the absolute change in HbA1c from baseline to 24-week endpoint of basal insulin glargine combination with exenatide bid vs. switching to aspart30 in type 2 diabetic patients inadequately controlled on premixed human insulin and metformin.